Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Moxibustion ; Spondylosis ; therapy ; Treatment Outcome

Objective To study the mRNA expression of HS1-associated protein X-1(Hax-1),an an- ti-apoptosis genc,in the peripheral blood mononuclear cells(PBMC)of patients with systemic lupus erythe- matosus(SLE),and further investigate the roles and significance of Hax-1 in the pathogenesis of SLE.Meth- ods Generation of longer cDNA fragments from serial analysis of gene expression(SAGE)tags for gene identi- fication(GLGI)was applied to identify the gene Hax-1 according to the Long SAGE tag.Then reverse tran- scription-polymerase chain reaction(RT-PCR)technique was used to semiquantitatively analyze mRNA ex- pressions of Hax-1 in PBMC from 34 active SLE patients and 25 healthy subjects.Results Compared with healthy controls,there was significant difference between SLE patients in the active stage and the normal controls(Z=-4.556,P＜0.01).The average level of mRNA expression in active SLE group was higher than that in healthy controls.Significant difference was found between the group with mild SLE and either the moderate or the severe one(P＜0.01).Conclusion The mRNA expression level of Hax-1 in active SLE group increase markedly,and to some extent,it is related to the activity of SLE.This provides a valuable basis for the further study on the role of apoptosis in SLE.

Background and objective Lung cancer is the leading cause of cancer-related deaths worldwide. Ap-proximately 15%of all histological types consist of small cell lung cancer (SCLC). Chemotherapy is one of the major treatment method. hTough the current ifrst-line standard chemotherapy regimen for SCLC is active in most SCLC cases, however the disease recurs shortly atfer the ifrst successful treatment with multi-drug resistance (MDR) phenotype. Our previously study showed that SPHK1 was associated with MDR in SCLC. hTe aim of this study is to investigate the role of sphingosine kinase 1 (SPHK1) showed in small cell lung multi-drug resistance. Methods Firstly, the analysis of QRT-PCR and Western blot were used to study differential expression of SPHK1 from mRNA and protein levels in both the H69 and H69AR cell lines. hTen, Downregulation of SPHK1 by transfection with siRNA in H69AR. Moreover, the sensitivities of cells to chemotherapy drugs such as ADM, DDP, VP-16 were detected by CCK8 assay. hTe change of cell cycle and apoptosis rate were detected by lfow cytometry. Meanwhile, expression of SPHK1 in clinical specimens were detected by QT-PCR and immunohistochemistry. Re-lation of SPHK1 expression with clinicopathological features and prognosis of patients was studied. Results hTe expression of SPHK1 was signiifcantly decreased in H69AR cells that in the H69 cells. hTe sensitivities of H69AR cells to chemotherapy drugs were increased when up-regulated the expression of SPHK1, enforced SPHK1 expression increased cell apoptosis and the cell cycle arrest in G0/G1 phase in H69AR cells, the expression of SPHK1 was not associated with gender, age, but signiif-cantly correlated with clinical stage, chemosensitivity and overall survival (P<0.05). Conclusion Our results suggest that SPHK1 is involved in the regulation of small cell lung cancer multi-drug resistance, SPHK1 may be as potentialtarget gene to evaluate the chemosensitivity and clinical prognostic for SCLC.

Objective To explore the expression of cancerous inhibitor of phosphatase 2A ( CIP2A) protein in small cell lung cancer and their relationship with clinicpathological features and prognosis. Methods A total of 112 cases of surgical specimens or bronchoscopic biopsies of small cell lung cancer were collected. There were specimens of 94 cases of SCLC tissues and 40 cases of paracancerous lung tissues. Quantitative RT?PCR and immunohistochemistry analysis were performed to determine the CIP2A expression in SCLC tissues. Kaplan?Meier curves were used to estimate the association between CIP2A expression and clinicopathological characteristics and prognosis of the patients. Results The expression of CIP2A in SCLC tissue was 7.605±1.893, significantly higher than that in the paracancerous tissues (1.041±0.786) (P<0.01) . The positive rate of CIP2A expression in cancer tissues was 82.8%, significantly higher than that in the paracancerous tissues (13.3%) (P<0.01). The median disease?free survival was 9.88 months in the CIP2A?high expressing patients, significantly shorter than the 20. 92 months in CIP2A?low expressing patients ( P<0.001) . CIP2A expression was significantly correlated with the tumor stage, chemotherapeutic sensitivity, and survival ( P<0. 05 for all ) . Conclusions CIP2A expression is associated with the pathogenesis of SCLC,and may become a potential prognostic indicator of SCLC.

Objective To explore the expression of cancerous inhibitor of phosphatase 2A ( CIP2A) protein in small cell lung cancer and their relationship with clinicpathological features and prognosis. Methods A total of 112 cases of surgical specimens or bronchoscopic biopsies of small cell lung cancer were collected. There were specimens of 94 cases of SCLC tissues and 40 cases of paracancerous lung tissues. Quantitative RT?PCR and immunohistochemistry analysis were performed to determine the CIP2A expression in SCLC tissues. Kaplan?Meier curves were used to estimate the association between CIP2A expression and clinicopathological characteristics and prognosis of the patients. Results The expression of CIP2A in SCLC tissue was 7.605±1.893, significantly higher than that in the paracancerous tissues (1.041±0.786) (P<0.01) . The positive rate of CIP2A expression in cancer tissues was 82.8%, significantly higher than that in the paracancerous tissues (13.3%) (P<0.01). The median disease?free survival was 9.88 months in the CIP2A?high expressing patients, significantly shorter than the 20. 92 months in CIP2A?low expressing patients ( P<0.001) . CIP2A expression was significantly correlated with the tumor stage, chemotherapeutic sensitivity, and survival ( P<0. 05 for all ) . Conclusions CIP2A expression is associated with the pathogenesis of SCLC,and may become a potential prognostic indicator of SCLC.

OBJECTIVETo understand clinical application of syndrome differentiation and treatment of meridians in acupuncture and moxibustion.

METHODSCollect and collate the literature about syndrome differentiation and treatment of meridians in Chinese Acupuncture & Moxibustion, Acupuncture Research, Shanghai Journal of Acupuncture & Moxibustion (Clinic edition B in 2003) and Clinical Journal of Acupuncture and Moxibustion from 2001 to 2003.

RESULTSLess literature about syndrome differentiation and treatment of meridians are involved, only accounting for 5.69% (163/2 864); and the literature about both treatment based on meridians and treatment based on syndrome differentiation of meridians only accounted for 1.22% (35/2 864).

CONCLUSIONAt present, clinically acupuncture and moxibustion do not play attention to treatment based on syndrome differentiation of meridians.

Acupuncture Points ; Acupuncture Therapy ; China ; Humans ; Meridians ; Moxibustion

Chrysoeriol is a natural flavonoid compound, which is widely present in many kinds of traditional Chinese medicine and medicinal herbs. In recent years, studies of Chrysoeriol on the pharmacological effects and its glycosides have gradually increased, especially in anti-tumor, anti-oxidative damage and anti-inflammatory immune regulation, etc., showing good pharmacological effects, and it has prospective potency as a candidate to develop new drug in those domain. This article briefly reviews the pharmacological effects and underlying mechanisms of chrysoeriol, so that researchers can understand the pharmacological characteristics of this compound, and also provide references for the development of new drugs based on this ingredient.

OBJECTIVETo study the roles of granzyme B and perforin in diagnosing acute rejection after liver transplantation, and the relationship between their activity index (AI) and Banff's histological grading criteria.

METHODSLiver biopsies were processed as for routine surgical specimens and labeled with granzyme B and perforin monoclonal antibodies. The number of positive cells/mm(2) was determined as activity index (AI) by IPP image analysis software. Histologic findings were used as the "gold standard" in diagnosing acute rejection.

RESULTSOf 41 liver biopsy samples studied, acute rejection was noted in 21 cases, the remaining 20 cases showed no evidence of rejection. The AI of granzyme B and perforin in the acute rejection group was significantly higher than that in the non-acute rejection group (< 0.001). In the acute rejection group, the AI in moderate to severe acute rejection was higher than that in mild to indeterminate acute rejection (< 0.001). Compared with the "golden" histologic criteria, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of granzyme B in diagnosing acute rejection were 90.0%, 95.2%, 94.7%, 90.9% and 92.7% respectively. The values of these parameters for perforin were also above 80%.

CONCLUSIONSGranzyme B and perforin are key markers of activated immune cells in acute rejection and highly expressed during acute liver rejection episodes. As ancillary investigations, these parameters demonstrated high sensitivity and specificity in diagnosing acute rejection in allograft post-transplant liver biopsies.

Biomarkers ; Biopsy ; Graft Rejection ; diagnosis ; metabolism ; Granzymes ; metabolism ; Humans ; Liver ; metabolism ; pathology ; Liver Transplantation ; immunology ; Membrane Glycoproteins ; metabolism ; Perforin ; Pore Forming Cytotoxic Proteins ; metabolism ; Sensitivity and Specificity

Adolescent ; Adult ; China ; epidemiology ; Female ; Humans ; Influenza A Virus, H1N1 Subtype ; Influenza, Human ; epidemiology ; Travel ; Young Adult

OBJECTIVESTo investigate the effects of antisense oligodeoxynucleotide(ASON) on the cyclic nucleotide monophosphates (cNMP) in smooth muscle cells of human corpus cavernosum, and provide experimental groundwork for the gene therapy of erectile dysfunction.

METHODSPDE5 gene ASON(containing exon 1) was transfected into the corpus cavernosum smooth muscle cells with the presence of liposome DOTAP. Another sense oligodeoxynucleotide(SON) and 1% of bovine serum were also transducted into the cells as controls. Two of cNMP, cAMP and cGMP, were probed and measured by ELISA at 1, 2, 4, 6, 10, 24 and 48 h after transfection.

RESULTSAfter transfection, the level of cGMP(1-6 h) in human corpus cavernosum smooth muscle cells was significantly higher than that in controls(P < 0.01).

CONCLUSIONSThe PDE5 gene ASON had been showed to manifest stimulative effect on the cGMP in smooth muscle cells of human corpus cavernosum in vitro, and it provides experimental groundwork for the gene therapy of erectile dysfunction.

3',5'-Cyclic-GMP Phosphodiesterases ; antagonists & inhibitors ; genetics ; Cyclic AMP ; metabolism ; Cyclic GMP ; metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 5 ; Humans ; Male ; Muscle, Smooth ; drug effects ; metabolism ; Oligodeoxyribonucleotides, Antisense ; pharmacology ; Penis ; cytology